Development and validation of method for TH588 and TH287, potent MTH1 inhibitors and new anti-cancer agents, for pharmacokinetic studies in mice plasma
2015 (English)In: Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, E-ISSN 1873-264X, Vol. 104, 1-11 p.Article in journal (Refereed) Published
MTH1 is a protein that is required for cancer cell survival and is overexpressed in cancer cells. TH588 and TH287 are two new compounds that inhibit the MTH1 protein. The inhibitors were tested in pharmacokinetic studies on mice. A bioanalytical method was developed and validated for determination in mice plasma. The method was based on protein precipitation followed by LC-MS/MS analysis. The separation was performed on an Ascentis Express RP-Amide C-18 column. The mass spectrometer was operated in positive electrospray ionization mode and the analytes were determined with multiple reaction monitoring (MRM). Abundant monoisotopic fragments were used for quantification. Two additional fragments were used for conformational analysis. The recovery of the compounds in plasma varied between 61 and 91% and the matrix effects were low and ranged between -3% and +2%. The method showed to be selective, linear, accurate and precise, and applicable for preclinical pharmacokinetic studies of TH588 and TH287 in mouse plasma. Half-life (T-1/2) was <= 3.5 h and maximum concentration (C-max) ranged between 0.82 and 338 mu M for the different administration routes and compounds.
Place, publisher, year, edition, pages
2015. Vol. 104, 1-11 p.
MTH1 inhibitors, TH588, TH287, LC-MS/MS bioanalysis, Validation
IdentifiersURN: urn:nbn:se:su:diva-115362DOI: 10.1016/j.jpba.2014.11.009ISI: 000348825900001PubMedID: 25459754OAI: oai:DiVA.org:su-115362DiVA: diva2:796823